

17th December 2015

Antisense Therapeutics to present at Biotech Showcase™ 2016

Antisense Therapeutics (ANP) is pleased to advise that Mark Diamond, ANP's CEO and Managing Director, will present at the Biotech Showcase conference on January 12 at 4.00pm in San Francisco, CA. The presentation will be webcast live and available on the Presentations page in the Investor Relations section of the Company's website at www.antisense.com.au.

Biotech Showcase is an investor and partnering conference held during the course of one of the industry's largest annual healthcare investor conferences (34th Annual J.P. Morgan Conference) when investors and biopharmaceutical executives from around the world gather in San Francisco.

Now in its eighth year, Biotech Showcase is expected to attract upwards of 2,100 attendees. Mark Diamond and one of the Company's new US based non-executive directors, William Goolsbee, will be in attendance to participate in meetings with US based investors and prospective pharmaceutical partners.

Contact Information:

Website: www.antisense.com.au

Managing Director: Mark Diamond +61 (0)3 9827 8999

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug designed to block GHr production which in a Phase II clinical trial, successfully reduced blood IGF-I levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.